JP2018516920A5 - - Google Patents

Download PDF

Info

Publication number
JP2018516920A5
JP2018516920A5 JP2017561971A JP2017561971A JP2018516920A5 JP 2018516920 A5 JP2018516920 A5 JP 2018516920A5 JP 2017561971 A JP2017561971 A JP 2017561971A JP 2017561971 A JP2017561971 A JP 2017561971A JP 2018516920 A5 JP2018516920 A5 JP 2018516920A5
Authority
JP
Japan
Prior art keywords
trastuzumab
administered
pharmaceutical
medicament
medicament according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017561971A
Other languages
English (en)
Japanese (ja)
Other versions
JP6822980B2 (ja
JP2018516920A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/034835 external-priority patent/WO2016196373A2/en
Publication of JP2018516920A publication Critical patent/JP2018516920A/ja
Publication of JP2018516920A5 publication Critical patent/JP2018516920A5/ja
Priority to JP2021001246A priority Critical patent/JP7330217B2/ja
Application granted granted Critical
Publication of JP6822980B2 publication Critical patent/JP6822980B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017561971A 2015-05-30 2016-05-27 Her2陽性転移性乳癌の治療方法 Active JP6822980B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021001246A JP7330217B2 (ja) 2015-05-30 2021-01-07 Her2陽性転移性乳癌の治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562168809P 2015-05-30 2015-05-30
US62/168,809 2015-05-30
PCT/US2016/034835 WO2016196373A2 (en) 2015-05-30 2016-05-27 Methods of treating her2-positive metastatic breast cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021001246A Division JP7330217B2 (ja) 2015-05-30 2021-01-07 Her2陽性転移性乳癌の治療方法

Publications (3)

Publication Number Publication Date
JP2018516920A JP2018516920A (ja) 2018-06-28
JP2018516920A5 true JP2018516920A5 (enExample) 2019-07-04
JP6822980B2 JP6822980B2 (ja) 2021-01-27

Family

ID=56134616

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017561971A Active JP6822980B2 (ja) 2015-05-30 2016-05-27 Her2陽性転移性乳癌の治療方法
JP2021001246A Active JP7330217B2 (ja) 2015-05-30 2021-01-07 Her2陽性転移性乳癌の治療方法
JP2023064033A Withdrawn JP2023100635A (ja) 2015-05-30 2023-04-11 Her2陽性転移性乳癌の治療方法
JP2025105921A Pending JP2025157247A (ja) 2015-05-30 2025-06-23 Her2陽性転移性乳癌の治療方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021001246A Active JP7330217B2 (ja) 2015-05-30 2021-01-07 Her2陽性転移性乳癌の治療方法
JP2023064033A Withdrawn JP2023100635A (ja) 2015-05-30 2023-04-11 Her2陽性転移性乳癌の治療方法
JP2025105921A Pending JP2025157247A (ja) 2015-05-30 2025-06-23 Her2陽性転移性乳癌の治療方法

Country Status (15)

Country Link
US (3) US11406715B2 (enExample)
EP (1) EP3302551B1 (enExample)
JP (4) JP6822980B2 (enExample)
CN (2) CN121971642A (enExample)
DK (1) DK3302551T3 (enExample)
ES (1) ES2984592T3 (enExample)
FI (1) FI3302551T3 (enExample)
HR (1) HRP20241134T1 (enExample)
HU (1) HUE068105T2 (enExample)
LT (1) LT3302551T (enExample)
PL (1) PL3302551T3 (enExample)
PT (1) PT3302551T (enExample)
RS (1) RS65871B1 (enExample)
SI (1) SI3302551T1 (enExample)
WO (1) WO2016196373A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210330801A1 (en) * 2017-03-02 2021-10-28 Cadila Healthcare Limited Novel protein drug conjugate formulation
US20200114018A1 (en) * 2018-10-15 2020-04-16 Genentech, Inc. Methods of treating residual breast cancer with trastuzumab emtansine
MA53933A (fr) 2018-10-21 2021-08-25 Slsg Ltd Llc Poly-immunothérapie pour le traitement du cancer du sein triple-négatif

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
EP0474727B1 (en) 1989-05-19 1997-07-23 Genentech, Inc. Her2 extracellular domain
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
ES2293661T3 (es) 1996-11-27 2008-03-16 Genentech, Inc. Purificacion por afinidad de polipeptido en una matriz de proteinas a.
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
PT1064027E (pt) 1998-03-27 2008-09-29 Genentech Inc Sinergismo de ligando de apo-2 e anticorpo anti-her-2
ATE370961T1 (de) 1998-05-06 2007-09-15 Genentech Inc Reinigung von antikörpern durch ionenaustauschchromatographie
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
SI1187632T1 (sl) 1999-05-14 2009-04-30 Genentech Inc Zdravljenje z anti-ErbB2 protitelesi
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
DE60033658T2 (de) 1999-06-25 2007-11-22 Genentech, Inc., South San Francisco Behandlung von prostata-krebs mit anti-erbb2 antikörpern
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US20030086924A1 (en) 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US20040013667A1 (en) 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
EP2110138A1 (en) 1999-08-27 2009-10-21 Genentech, Inc. Dosages for treatment of anti-erbB2 antibodies
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
WO2001089566A1 (en) 2000-05-19 2001-11-29 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
US6984494B2 (en) 2000-08-15 2006-01-10 Genentech, Inc. Analytical method
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
JP2005522514A (ja) 2002-04-10 2005-07-28 ジェネンテック・インコーポレーテッド 抗her2抗体改変体
HUP0600340A3 (en) 2002-07-15 2011-06-28 Genentech Inc Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies
PT1543038T (pt) 2002-09-11 2017-07-07 Genentech Inc Purificação de proteína
EP1572972A4 (en) 2002-11-21 2007-11-21 Genentech Inc THERAPY OF NON-MALIGNER DISEASES OR DISORDER WITH ANTI-ERBB2 ANTIBODIES
JP4599355B2 (ja) 2003-07-28 2010-12-15 ジェネンテック, インコーポレイテッド プロテインaアフィニティークロマトグラフィーの間のプロテインaの浸出の低減
US7004206B2 (en) 2004-01-29 2006-02-28 Viken James P Automatic fluid exchanger
AU2005232657B2 (en) 2004-04-08 2010-12-16 David B. Agus ErbB antagonists for pain therapy
NZ551180A (en) 2004-06-01 2009-10-30 Genentech Inc Antibody drug conjugates and methods
SV2006002143A (es) 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
UA90480C2 (uk) 2004-07-22 2010-05-11 Джэнэнтэк, Инк. Фармацевтична композиція, що має протипухлинну активність, яка включає антитіло до her2
CA2577133A1 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA2587519A1 (en) 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a her inhibitor
EP3698807A1 (en) 2005-01-21 2020-08-26 Genentech, Inc. Fixed dosing of her antibodies
RS53128B (sr) 2005-02-23 2014-06-30 Genentech Inc. Produžavanje vremena progresije bolesti ili preživljavanja kod pacijenata obolelih od kancera jajnika korišćenjem pertuzumaba
US20060204505A1 (en) 2005-03-08 2006-09-14 Sliwkowski Mark X Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
US20060212956A1 (en) 2005-03-14 2006-09-21 Genentech, Inc. Animal model of ligand activated HER2 expressing tumors
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Herceptin(登録商標)補助療法
US20070009976A1 (en) 2005-07-06 2007-01-11 Helmut Lenz Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
PE20070207A1 (es) 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US7700299B2 (en) 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
NZ567140A (en) 2005-10-07 2011-09-30 Exelixis Inc Azetidines as MEK inhibitors for the treatment of proliferative diseases
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
AU2007259171A1 (en) 2006-06-05 2007-12-21 F. Hoffmann-La Roche, Ag Extending survival of cancer patients with elevated levels of EGF or TGF-alpha
AU2007287794B2 (en) 2006-08-21 2013-03-28 F. Hoffmann-La Roche Ag Tumor therapy with an anti-VEGF antibody
WO2008031531A1 (en) 2006-09-15 2008-03-20 F. Hoffmann-La Roche Ag Tumor therapy with a combination of anti-her2 antibodies
MX2009008981A (es) 2007-03-02 2009-09-02 Genentech Inc Prediccion de respuesta a un inhibidor her.
AU2008258859A1 (en) 2007-06-06 2008-12-11 F.Hoffmann-La Roche Ag Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a NIR fluorescence label
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
WO2008154249A2 (en) 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
BRPI0816769A2 (pt) 2007-09-12 2016-11-29 Hoffmann La Roche combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso
HUE024877T2 (en) 2007-10-30 2016-02-29 Genentech Inc Antibody purification by cation exchange chromatography
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至her2結構域ii之抗體及其酸性變異體的組合物
CL2009000545A1 (es) 2008-03-06 2010-10-15 Genentech Inc Uso de un antagonista de c-met y un antagonista de her para el tratamiento de cancer.
NZ587706A (en) 2008-03-18 2012-12-21 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
US20120121586A1 (en) 2009-05-29 2012-05-17 Astrid Kiermaier Modulators for her2 signaling in her2 expressing patients with gastric cancer
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
WO2011069074A2 (en) * 2009-12-04 2011-06-09 Genentech, Inc. Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1
WO2012078771A1 (en) 2010-12-09 2012-06-14 Genentech, Inc. Treatment of her2-positive cancer with paclitaxel and trastuzumab-mcc-dm1

Similar Documents

Publication Publication Date Title
JP2020509024A5 (enExample)
EA201650134A1 (ru) Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
JP2017226708A5 (enExample)
RU2016112608A (ru) Лечение рака комбинацией плинабулина и таксана
RU2020120593A (ru) Способы лечения раннего рака молочной железы трастузумабом-mcc-dm1 и пертузумабом
JP2012506448A5 (enExample)
JP2020523356A5 (enExample)
JP2018522028A5 (enExample)
JP2016515586A5 (enExample)
JP2012522837A5 (enExample)
JP2018526460A5 (enExample)
JP2017514854A5 (enExample)
RU2016147521A (ru) Способы применения антител к ang2
JP2019534251A5 (enExample)
MX2023007826A (es) Metodos que comprenden una dosificacion intermitente fija de cediranib.
RU2012108144A (ru) Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами
WO2015038896A3 (en) Wilforlide a for overcoming chemotherapy resistance
JP2023539154A5 (enExample)
WO2017013490A3 (en) Therapeutic combinations of orally administered paclitaxel and a p-gp inhibitor for the treatment of cancer
RU2018114457A (ru) Лечение syd985 пациентов с t-dm1 рефрактерным раком
FI3302551T3 (fi) Menetelmiä her2-positiivisen, aiemmin hoitamattoman metastaattisen rintasyövän hoitamiseksi
RU2015145948A (ru) Противоопухолевый агент, включающий гидрат гидрохлорида иринотекана
JP2020524164A5 (enExample)
JP2016522826A5 (enExample)
JP2015529664A5 (enExample)